Alpha-synuclein and mitochondrial permeability transition pore interactions in rotenone-induced Parkinson’s disease models: neuroprotective promise of cyclosporine A Authors: Sukhpal Singh, Aritri Bir, Rahul Thakur, Aman Chauhan, Arindam Ghosh, Amit Mittal, Amit Kumar Nayak, Sankha Shubhra Chakrabarti, Sasanka Chakrabarti Published: 2026 ABSTRACT AbstractBackgroundRotenone is widely used to develop experimental models of Parkinson’s disease, but the varied toxic effects of rotenone are still not mechanistically linked to define a clear pathway of neuronal damage.MethodsThe neurotoxicity of rotenone in rats, with or without co-treatment with cyclosporine A (an inhibitor of mitochondrial permeability transition pore (mPTP) activation), has been examined in terms of neuronal death in the substantia nigra and dysfunction of isolated midbrain mitochondria. Additionally, the role of α-synuclein on rotenone-induced cell death and mitochondrial dysfunction has been explored in SH-SY5Y cells.ResultsIn rats, nigral dopaminergic neuronal death and α-synuclein accumulation along with altered functions of midbrain mitochondria are observed after rotenone treatment; the co-treatment with cyclosporine A prevents neuronal death and all mitochondrial alterations (except complex I-III inhibition) without having a noticeable effect on α-synuclein accumulation. Likewise, in SH-SY5Y cells, exposure to rotenone for 48 h leads to cell death and mitochondrial dysfunction, which are abolished by the knockdown of α-synuclein protein expression.ConclusionTogether, the results suggest the pivotal role of α-synuclein in causing mitochondrial dysfunction and neural cell death presumably through mPTP activation. Further, cyclosporine A may have a potential neuroprotective effect in PD.Keywords: Mitochondria, Rotenone, α-Synuclein, Cyclosporine A, Neuroinflammation, Reactive oxygen species Introduction The pathogenesis of sporadic Parkinson’s disease (PD), the most prevalent form of the disease, presumably results from interactions among aging, genetic risk factors, and multiple environmental and lifestyle factors interacting through complex intracellular damage pathways [1,2]. Pathologically, the disease shows a characteristic loss of dopaminergic neurons in the substantia nigra that project to the striatum, which accounts for the motor disability in PD, but other parts of the brain and non-dopaminergic neurons are also affected [1,2]. The appearance of cytoplasmic inclusions called Lewy bodies (LBs), primarily composed of the protein α-synuclein, in degenerating dopaminergic neurons is also a characteristic feature of PD pathology [[2], [3], [4]]. The underlying mechanisms of PD pathogenesis are not fully elucidated, but oxidative stress, mitochondrial dysfunctions, and the accumulation and aggregation of α-synuclein are some of the suggested mechanisms that interact in varied ways, resulting in the neuronal death of PD [3,5,6]. Oxidative stress in the PD brain can arise from dopamine oxidation, excess iron accumulation, mitochondrial dysfunction, activated microglia, mutated familial PD-linked gene products (α-synuclein, Parkin, DJ-1, and others), and other mechanisms [2,5]. The accumulation of oxidative damage markers and decreased levels of reduced glutathione in post-mortem PD brain, especially in the substantia nigra, have been well-documented, and such evidence of oxidative stress in the brain is also observed in experimental models of PD [2,5,7]. In particular, oxidative stress, mitochondrial dysfunction, and α-synuclein accumulation or aggregation are interacting damage pathways that finally lead to dopaminergic neurodegeneration through failure of cellular bioenergetics or activation of regulated cell death pathways [2,[5], [6], [7]]. Both post-mortem studies of PD brains and experiments with genetic or toxin-induced PD models have contributed to our understanding of PD pathogenesis. Toxin-based models using animals or non-mammalian species, or cultured primary mesencephalic neurons or dopaminergic cell lines, commonly employ rotenone, 6-hydroxydopamine, or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); these have provided important clues not only for understanding PD pathogenesis but also for identifying potential neuroprotective compounds for this disease [7,8]. Rotenone-induced animal models of PD, in addition to exhibiting characteristic motor deficits and degeneration of nigrostriatal dopaminergic neurons, also exhibit several important pathogenic features of PD, such as mitochondrial complex I inhibition, oxidative stress, α-synuclein accumulation, and aggregation [9,10]. However, these different processes of rotenone toxicity in such PD models were not clearly linked in a common pathway of damage, and additionally multiple other toxic effects of rotenone were suggested from in vitro studies [11]. Thus, it is necessary to explore further the mechanisms of rotenone toxicity in experimental models of PD. In this context, we showed recently that rotenone toxicity in SH-SY5Y cells (a human dopaminergic neuroblastoma cell line) was not simply a consequence of mitochondrial complex I inhibition; instead, the neuronal death was predominantly mediated by the activation of the mitochondrial permeability transition pore (mPTP) causing a failure of mitochondrial bioenergetics and enhanced production of reactive oxygen species (ROS) [12]. The precise structural components of mPTP, especially in the pore-forming conformation, are yet to be established with certainty, but the activation of this non-selective channel leads to diffusion of molecules less than 1.5 kDa across the inner mitochondrial membrane with osmotic swelling of mitochondria, stoppage of oxidative phosphorylation, increased ROS production, and eventual cell death [13,14]. Cyclosporine A, which inhibits the opening of mPTP by binding to mitochondrial matrix cyclophilin D, was able to prevent markedly the death of SH-SY5Y cells caused by rotenone in our model; additionally, cyclosporine A prevented the neurobehavioral deficits and nigro-striatal dopaminergic neurodegeneration in rotenone treated rats [12]. In the current study, we further explored the mechanisms of rotenone toxicity in both rat brain and SH-SY5Y cells. Firstly, we have attempted to verify whether rotenone toxicity in rat brain also involves mPTP activation, with consequent bioenergetic failure, rather than the simple complex I inhibition observed earlier in SH-SY5Y cells. Secondly, the accumulation of α-synuclein in rodent brain and SH-SY5Y cells after rotenone treatment in experimental PD models was reported by others [9,15]. We wanted to verify whether α-synuclein accumulation is causal for mitochondrial dysfunction and neural cell death in such models, so that a pathway of damage can be clearly delineated. Materials and Methods Treatment protocols for animals The study was approved by the Animal Ethical Committee of the institute and conducted as per the guidelines (approval no. MMIMSR/961 dated 29.07.2022). Wistar rats of both sexes (total 51, 29 male, 22 female), aged 6–8 months, were housed in polypropylene cages with free access to commercial rat chow and water and maintained under a 12-h day/night cycle at 25°C ± 1°C. Rats were randomly assigned to three groups: control group with rats injected intraperitoneally with the vehicle [sterile sunflower oil (98%) plus 2% dimethyl sulphoxide or DMSO (HiMedia, India)] for 8 consecutive days; the rotenone group treated with rotenone (Sigma, USA) intraperitoneally (1.5 mg/kg body-weight) dissolved in the vehicle for 8 consecutive days, and the third group (Rot + CsA) where rats were orally administered with cyclosporine A (purchased from the hospital pharmacy) at a dose of 10 mg/kg body-weight daily, beginning 7 days prior to rotenone treatment and continuing throughout the 8-day period of intraperitoneal rotenone treatment. The method was adopted from our earlier published work [12]. There was no mortality in any of the groups during the treatment schedule. At the end of the treatment schedule, rats were sacrificed for immunohistochemical or fluorescence imaging studies or determination of the mitochondrial parameters. Isolation of brain mitochondria The animals were decapitated, brains removed over an ice-cold Petri dish, and quickly dissected to obtain midbrain and striatum. Mitochondria were isolated from the combined midbrain and striatal tissues by differential centrifugation and treatment with digitonin (SRL, India) as published earlier [16]. The final mitochondrial pellet was resuspended either in the incubation buffer IB (145 mM KCl, 50 mM sucrose, 5 mM NaCl, 1 mM EGTA, 1 mM MgCl2, and 10 mM phosphate buffer, pH 7.4) or in 50 mM phosphate buffer, pH 7.4, as required for subsequent experiments. Measurement of mitochondrial functional parameters and ROS production in vitro The membrane potential of isolated mitochondria incubated at 37°C for 30 min in IB in the presence of 10 mM pyruvate, 10 mM succinate, 1 mM ADP (SRL, India) was determined using the mitochondrial membrane potential-sensitive fluorescence probe 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide (JC-1, Sigma, USA), as previously published by us [16,17]. Aliquots of freshly prepared mitochondria in IB were utilized for assessing ATP production in vitro during an incubation for 15 min in the presence of pyruvate (10 mM), succinate (10 mM), and ADP (1 mM); ATP was estimated luminometrically employing a luciferin-luciferase-based assay kit (Sigma, USA), as adopted from our earlier publication [17]. The quantification of H2O2 production by isolated brain mitochondria incubated in IB containing 10 mM pyruvate, 10 mM succinate, and 1 mM ADP for 15 min at 37°C was done using the fluorogenic dye N-acetyl-3,7-dihydroxyphenoxazine or Amplex Red (Sigma, USA) as published earlier [16]. The amount of H2O2 formed during the incubation period of 15 min incubation period was calculated using a calibration curve and normalized to the protein content of each mitochondrial sample. For the analysis of respiratory complexes, an aliquot of mitochondrial suspension in 50 mM phosphate buffer, pH 7.4, was suitably diluted in 10 mM phosphate buffer, pH 7.4, followed by three cycles of freeze-thawing prior to the assay. Spectrophotometric determination of mitochondrial complex I-III and complex II-III activities was conducted as described in earlier publications [17,18]. Immunohistochemical staining Immunohistochemical analysis of the substantia nigra, targeting tyrosine hydroxylase (TH) or α-synuclein, was conducted following standard protocols. In brief, the animal was anesthetized and the brain perfused with 4% paraformaldehyde in phosphate-buffered saline (PBS) to effectively wash out blood from the cerebral vasculature; serial coronal sections of 15 μm thickness were obtained spanning the substantia nigra using a cryostat microtome (Leica, Germany) and collected on slides coated with poly-l-lysine (Sigma, USA) and processed as described in earlier publication [12]. The primary antibodies used for different targets were: a rabbit polyclonal primary antibody (Invitrogen, USA) diluted 1:2000 for α-synuclein, and a mouse monoclonal antibody (Santa Cruz, USA) diluted 1:50 for TH. The secondary antibodies were: fluorescein isothiocyanate (FITC)- conjugated goat anti-rabbit IgG (Genei, India) diluted 1:4000 for the detection of α-synuclein and horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG (Abcam, USA) diluted 1:300 for the detection of TH. Finally, images were captured using a fluorescence microscope (Carl Zeiss, Germany) for FITC-labelled secondary antibody or a light microscope (Labovision, India) for HRP-labelled secondary antibody employing a 3, 3′-diaminobenzidine (DAB)-based chromogen; several random images were captured from each section, and representative images are presented. Further, the quantification of images was performed using Image J for the purpose of statistical analysis. Propidium iodide (PI) staining of brain cryosections The tissue sections were initially fixed with 70% ethanol for a duration of 10 min, followed by two subsequent rinses in PBS. Subsequently, the tissues were incubated with 1 μM PI (Sigma, USA) solution in PBS for 20 min at 37°C. After the incubation period, the stained sections were washed in PBS to remove any excess dye. Finally, the sections were examined under a fluorescence microscope (Carl Zeiss, Germany), and multiple images were randomly captured for each section. The quantification of images was performed using Image J. Cell culture SH-SY5Y cells (ATCC, USA) were grown in cell culture flasks or multi-well plates in a medium of 2 vol of DMEM (Sigma, USA) and 1 volume of F12 Ham’s medium (Sigma, USA) containing 10% fetal bovine serum (FBS) (Gibco, USA), penicillin (50 units/mL), streptomycin (50 μg/mL) and amphotericin B (2.5 μg/mL) at 37o C under an atmosphere of 5% CO2 and 95% air; all incubations of cells for experiments were conducted under similar conditions. Transfection of cells and treatment protocols SH-SY5Y cells were either non-transfected (Wild type) or transfected with α-synuclein-specific siRNA (Santa Cruz, USA) to knock down the expression of α-synuclein protein (α-Syn KD) or transfected with scrambled siRNA (Santa Cruz, USA) named ‘Scram’. The transfection experiments were conducted using the Xfect transfection kit (Takara, USA) following the manufacturer’s instructions, with some adaptations as previously reported by us; the final siRNA concentration during transfection was 12 nM [19,20]. The validation of knockdown of α-synuclein protein expression in SH-SY5Y cells was performed by immunoblotting. The lysates from cells (Wild type, α-Syn KD, and Scram cells incubated for 48 h without or with 0.5 μM rotenone) were analyzed for α-synuclein content after sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting, as adapted from an earlier published procedure [19]. The rabbit polyclonal anti-α-synuclein antibody (Thermo Fisher, USA) was used as the primary antibody (1:1000 dilution), while horseradish peroxidase (HRP) – conjugated anti-rabbit IgG (Abcam, USA) was employed as the secondary antibody (1: 2000 dilution). The blot was developed by the enhanced chemiluminescence method and imaged using a gel documentation system (Azure Biosystems, USA); β-actin was used as the loading control. The quantification of band intensities in representative blots was performed by using ImageJ. For experimental purposes, the Wild type, α-Syn KD, and Scram cells were incubated without or with 0.5 μM rotenone at 37o C for 48 h and analyzed for cell death and mitochondrial functional parameters. Cell death assays Cell death was assessed by a fluorometric method using double-staining with Hoechst 33258 (Sigma, USA) and PI (Sigma, USA). In this assay, the membrane-permeable Hoechst 33258 enters both live and dead cells and binds to double-stranded DNA in the nucleus, emitting blue fluorescence; on the other hand, PI enters only the dead cells with compromised membrane integrity and binds to nuclear DNA by intercalation, emitting red fluorescence. The higher ratio of red fluorescence to blue fluorescence is thus indicative of a higher percentage of cell death. In brief, the cells from each well were harvested in PBS by routine trypsinization protocol and treated with cold 70% methanol for 10 min for fixation of cells. The cells were collected by centrifugation and washed twice in PBS. The resulting pellet was re-suspended in PBS and incubated for 20 min with shaking at 37°C in the dark with a staining solution containing 1 μg/mL Hoechst 33258 and 1 μM PI. At the end of the incubation, the cells were collected by centrifugation and washed twice more in PBS. The final cell pellet was resuspended in 200 μL of PBS, and fluorescence emissions were measured on a multi-mode microplate reader (Molecular Devices, USA) at λex 350 nm/λem 461 nm for Hoechst 33258 and λex 493 nm/λem 636 nm for PI. The method was validated by using several well-known cytotoxic agents. In another cell death assay, LDH released into the medium from dead cells was quantified by the pyruvate-linked oxidation of NADH (SRL, India), monitored by the decrease in absorbance at 340 nm [12]. The LDH activities were expressed as percentages of LDH released in wells with 100% cell death (cells treated with 10 μM of antimycin A (Sigma, USA) for 48 h) [12]. Assessment of mitochondrial functional parameters in SH-SY5Y cells The mitochondrial membrane potential of intact cells was determined by using the fluorescence probe tetramethylrhodamine ethyl ester (TMRE) (Sigma, USA), and the intracellular ATP content was estimated by the luciferin-luciferase based assay using a commercial kit (Sigma, USA); both methods were adopted from our earlier publication with cells grown on multi-well plates [12,19]. For mitochondrial membrane potential, fluorescence intensity (arbitrary fluorescence units) measured in a microplate reader (Molecular Devices, USA) from each well was normalized to the same protein content and finally expressed as a percentage relative to control cells. In the case of the ATP assay, the chemiluminescence intensity measured with a microplate reader for each sample was converted to ATP content using a calibration curve, then normalized to the same protein content for each well; the values were finally presented as percentages of the control. Mitochondrial ROS production was measured using the fluorogenic probe MitoSox red (Thermo Fisher, USA), a cationic derivative of dihydroethidium that selectively accumulates within mitochondria and is oxidized by superoxide radicals to generate red fluorescence. In brief, after removing the media from each well, the adherent monolayer of cells in 12-well plates was gently washed twice with PBS and subsequently incubated at 37°C for 30 min in serum-free medium containing 5 μM MitoSox red in the dark. At the end of the incubation, the cells were rinsed twice with PBS and then covered with 500 μL of PBS. The fluorescence was measured using a multi-mode microplate reader (λex 510 nm, λem 580 nm); the emission intensity from each well was normalized to the identical protein content, and expressed as the percentage relative to the control. Protein estimation Protein was estimated in samples using the bicinchoninic acid or BCA (Sigma, USA) assay. Statistical analysis Statistical comparisons among different groups were made by one-way analysis of variance (ANOVA) followed by post-hoc Tukey’s test; the data normality was confirmed by the Shapiro-Wilk test before applying ANOVA. The number of animals used for each analysis in each group, or the number of independent biological replicates in cell-based studies, for each parameter was calculated using the Resource Equation [21]. The value of n for each parameter is shown in the corresponding figure legend; a p-value of ≤ 0.05 was considered statistically significant. The data analysis was performed by GraphPad Prism software (version 8.4). For immunohistochemistry and fluorescence imaging studies, the number of independent observations for each group has been limited to 3 only. Results Mitochondrial alterations in rotenone treated rats: protection by cyclosporine A Mitochondria isolated from the midbrain and striatal regions were analyzed in vitro for several functional parameters in three groups of rats: control, rotenone, and Rot + CsA. Since rotenone is a classical inhibitor of mitochondrial complex I, we first measured the respiratory chain complex activities. Mitochondrial complex I-III activity was expectedly diminished by around 46% in the rotenone group with respect to control group, but cyclosporine A co-treatment (Rot + CsA group) failed to prevent this (Fig. 1A). As shown in Fig. 1B, the activities of mitochondrial complex II-III remained nearly similar in all three groups. Mitochondrial alterations in rotenone-induced PD rat model: protection by cyclosporine A Functional parameters were analyzed in isolated mitochondria from control, rotenone and Rot + CsA groups of rats. Complex I-III activity (A), complex II-III activity (B), transmembrane potential (C), H2O2 production (D) and ATP synthesis rate (E) were measured as described in the text. Values are the means ± SEM, n = 8 in (A), n = 6 in (B), (C), (D), (E). Statistical analyses were performed by one-way ANOVA followed by post-hoc Tukey’s test; p ≤ 0.05 was considered as statistically significant; A: [F2,21 = 6.031, p = 0.0085, significant differences among groups, post-hoc p = 0.0062 between the control and rotenone groups, non-significant (p = 0.2626) in rotenone versus Rot + CsA groups]; B: [ statistically non-significant in both ANOVA and post-hoc tests]; C, D, E: [F2,15 = 13.60, p = 0.0004; F2,15 = 21.62, p < 0.0001; F2,15 = 16.21, p = 0.0002 respectively indicating significant differences across groups in each Figure; Tukey’s post-hoc comparisons, p values indicating statistically significant differences, control versus rotenone groups, rotenone versus Rot + CsA groups]. For other parameters, we observed that in the rotenone group the mitochondrial membrane potential was decreased by nearly 50%, ROS production increased by around 2.3-fold, and ATP synthesis decreased by around 55% with respect to control, and all these effects were markedly prevented by co-treatment with cyclosporine A in the Rot + CsA group (Fig. 1C, D, E). Thus, these mitochondrial alterations induced by rotenone are apparently independent of inhibition of complex I-III activity because the latter is not prevented by cyclosporine A. Dopaminergic neuronal death and α-synuclein accumulation in PD rat model In order to understand the implications of rotenone induced mitochondrial dysfunction in the context of nigral dopaminergic neuronal death, we performed the immunohistochemistry of TH-positive neurons in the substantia nigra. On the cryostat sections in the region of substantia nigra, a remarkable loss of TH-immunoreactivity could be seen in the rotenone group compared to control; a conspicuous recovery of TH-positivity, however, was observed by co-treatment with cyclosporine A in the Rot + CsA group of animals as shown in the representative images (Fig. 2A, upper panel). When quantification in terms of number of TH-positive neurons per field, percentage areas of TH-positivity per field, and integrated density were performed, significant decreases in all parameters were noted after rotenone treatment, and cyclosporine A co-treatment markedly ameliorated the rotenone effects (Fig. 2B; a, b, c). The protective actions of cyclosporine A on rotenone induced mitochondrial dysfunction and dopaminergic neuronal death suggests that mitochondrial dysfunction is causal to neurodegeneration in this PD model. Cyclosporine A effects on neuronal death and α-synuclein accumulation in substantia nigra in rotenone-induced PD models A. Representative images of immunohistochemistry of TH-positivity (upper panel), PI staining (middle panel), and immunofluorescence imaging of α-synuclein (lower panel) are shown from nigral cryosections of control, rotenone and Rot + CsA groups of rats as described in the text. B. Quantification and statistical analyses were performed for all imaging parameters in control, rotenone and Rot + CsA groups (3 animals in each group for each parameter). TH-positivity parameters in a, b, c [one way ANOVA shows significant differences among groups; (a) F2,6 = 131.4, p < 0.0001; (b) F2,6 = 13.43, p = 0.0061; (c) F2,6 = 14.68, p = 0.0049; post-hoc Tukey’s test, p values indicate significant differences, control versus rotenone and rotenone versus Rot + CsA, for all 3 TH-positivity parameters]; PI staining in d [significant differences among groups by one-way ANOVA, F2,6 = 139.3, p < 0.0001; Tukey’s test, p < 0.0001 for control versus rotenone, and rotenone versus Rot + CsA]; Immunofluorescence of α-synuclein in e [one-way ANOVA indicates significant group differences, F2,6 = 11.42, p < 0.0090; Tukey’s test, p values indicate significant difference in control versus rotenone, non-significant in rotenone versus Rot + CsA]. When the nigral cryo-sections were stained with the membrane-impermeable PI and examined under a fluorescence microscope, numerous bright red fragmented nuclei from dead neurons could be observed in the rotenone treated animals than in control animals or Rot + CsA animals (Fig. 2A, middle panel). The quantification of fluorescence intensity in cryo-sections showed significantly higher PI fluorescence intensity in the rotenone group than in control or Rot + CsA group (Fig. 2B–d). These results are consistent with our findings on the loss of TH-positive neurons by rotenone treatment and its protection by cyclosporine A. The accumulation of α-synuclein was examined by immunofluorescence imaging in the nigral region. α-Synuclein aggregates with conspicuous green fluorescence could be seen both in the rotenone group and Rot + CsA rats but not in control animals (Fig. 2A, lower panel). The quantification of fluorescence intensity of α-synuclein was also performed, which revealed that cyclosporine A treatment had no major effect on rotenone induced accumulation of α-synuclein (Fig. 2B–e). This interesting finding clearly suggests that the protective effect of cyclosporine A is related to its ability of blocking the deleterious actions of α-synuclein instead of preventing the build-up of this toxic protein. It may be clearly stated that immunohistochemistry and fluorescence imaging studies were performed with only 3 animals in each group for each parameter set; although statistically significant differences were seen clearly among the groups as indicated in the figures and legends, the statistical power of such analyses would be low because of small sample size. For other biochemical assays, an adequate sample size was determined as explained in the Statistical Analysis section. Knockdown of α-synuclein protein expression prevents rotenone toxicity in SH-SY5Y cells Based on the results from our animal model of PD, we ventured to further probe the role of α-synuclein in rotenone induced neuronal death in a cell based model. For this purpose we examined the cytotoxic effects of rotenone on SH-SY5Y cells with or without silencing the expression of α-synuclein protein. Non-transfected (Wild type) SH-SY5Y cells and those transfected with either α-synuclein-specific siRNA to reduce α-synuclein protein expression (α-Syn KD) or with scrambled siRNA (Scram) were exposed to rotenone (0.5 μM) for 48 h. The knockdown of α-synuclein protein expression was validated by immunoblotting, which is presented in the Supplementary Fig. S1(A, B) for the current study, we conducted two sets of knockdown experiments to obtain all our desired results. The knockdown protocol was standardized by our research group very well and published earlier also [19,20]. Results presented in Fig. 3A and B show dramatic cell death, measured by the fluorometric PI/Hoechst 33258 ratio and the LDH release assay, respectively, after 48 h of rotenone treatment in both Wild type and Scram cells, whereas in α-Syn KD cells, rotenone induced cell death was completely abolished. On examination of cell morphology under an inverted microscope (Fig. 3C), it was observed that rotenone induced a drastic change in cell morphology in Wild type and Scram cells but not in α-Syn KD cells (Fig. 3C). α-Synuclein knockdown in SH-SY5Y cells prevents rotenone cytotoxicity. The viability and morphology were analyzed in three groups of cells (Wild type, α-Syn KD, Scram) after incubation without or with rotenone as described in the text. A: Cell death assay by fluorometric double-staining method (PI/Hoechst 33258). B: Cell death measurement by LDH release assay (LDH activities expressed as % of LDH released in wells with 100 percent cell death as detailed in the Materials and Methods). The values are the means ± SEM; n = 6 [one-way ANOVA among groups; Fig. 3A: F5,30 = 519.0, p < 0.0001; Fig. 3B: F5,30 = 495.6, p < 0.0001; Tukey's post-hoc test in Fig. 3A and B: very significant effect (p < 0.0001) of rotenone on cell death in Wild type and Scram cells, non-significant effect of rotenone on cell death in α-Syn KD cells]. C. The morphology of cells (Wild type, α-Syn KD and Scram) was examined under bright field inverted microscopy after rotenone treatment. Upper panel: cells without rotenone treatment; Lower panel: cells exposed to rotenone. α-Synuclein knockdown prevents rotenone induced mitochondrial impairment Finally, we assessed the rotenone effects on mitochondrial functions in SH-SY5Y cells with knockdown of α-synuclein protein expression. Results in Fig. 4A show that in Wild type SH-SY5Y cells and Scram cells, 48 h of rotenone treatment caused a pronounced decrease in mitochondrial transmembrane potential, but the knock down of α-synuclein expression (α-Syn KD cells) markedly abolished the rotenone effect. Rotenone caused a marked depletion of ATP content in Wild type and Scram cells, but in α-Syn KD cells the rotenone effect was mitigated considerably (Fig. 4B). A noticeable increase (around 7-fold) in mitochondrial ROS production was observed after rotenone treatment of Wild type or Scram cells for 48 h, but the rotenone effect was abolished in α-Syn KD cells (Fig. 4C). Silencing of α-synuclein expression prevents mitochondrial dysfunctions on rotenone exposure. SH-SY5Y cells (Wild type, α-Syn KD and Scram) were incubated without or with rotenone and analyzed for mitochondrial membrane depolarization by TMRE assay (A), cellular ATP level (B) and mitochondrial ROS production by using MitoSox red (C). Values are calculated as % of Wild type without rotenone treatment. Results are presented as the means ± SEM from four (A, B) and six (C) independent experiments. One-way ANOVA across all groups in each Figure was applied; A: [F5,18 = 269.0, p < 0.0001], B: [F5,18 = 279.4, p < 0.0001], C: [F5,30 = 319.7, p < 0.0001]; Tukey’s post-hoc test among the groups in each figure [significant differences (p < 0.0001) between rotenone treated and untreated (-rotenone) groups in Wild type and Scram SH-SY5Y cells, but statistically non-significant effect of rotenone in α-Syn KD cells]. Discussion In our PD models of rats, rotenone treatment leads to profound mitochondrial alterations such as complex I-III inhibition, membrane depolarization, diminished capacity of ATP synthesis and enhanced ROS production as examined in isolated mitochondria from the midbrain and striatum; all rotenone effects are prevented significantly by co-administration of oral cyclosporine A with the notable exception of the inhibition of complex I-III (Fig. 1). On examination of TH-immunoreactivity in substantia nigra, it is observed that the rotenone induced loss of dopaminergic neurons is markedly prevented by the co-administration of oral cyclosporine A (Fig. 2A and B–a,b,c). Taken together, the results from animal studies confirm the central role of mPTP activation with consequent derangement of mitochondrial bioenergetics in rotenone-induced neuronal death in PD models. The results also emphasize the fact that complex I-III inhibition by rotenone per se is not responsible for neuronal death because cyclosporine A is capable of preventing the neuronal death without rescuing the complex I-III activity. These in vivo effects of rotenone on mitochondria in rat midbrain strongly validate our earlier published results on SH-SY5Y cells [12]. Some other studies suggested that oxidative damage was a key element of rotenone toxicity in PD animal models, which was attributed to the inhibition of complex I activity by this toxin [22]. However, our results have clearly shown that increased ROS production by isolated mitochondria from rotenone treated rats is markedly prevented by the co-treatment with cyclosporine A which implies that the process is likely to be a consequence of mPTP opening (Fig. 1). Interestingly, we observed a large number of PI-stained fragmented nuclei in substantia nigra in rotenone treated animals (Fig. 2A). In primary necrosis of cells, the nucleus is not fragmented and it appears as a swollen uniformly red round structure after PI staining. It is plausible that in our animal model after rotenone treatment, an initial apoptosis of nigral neurons with chromatin condensation and nuclear fragmentation (karyorrhexis) took place forming apoptotic bodies with intact membrane; this was followed by the secondary necrosis with disruption of cell membranes and release of cellular contents [23]. This process resulted in the conspicuous appearance of red PI-stained fragments of nuclei in the nigral region of rotenone treated rats. The rotenone effect was, however, prevented by cyclosporine A suggesting the involvement of mPTP activation in this process (Fig. 2A). It is important to remember that mPTP activation is mechanistically linked to both apoptosis and necrosis [13]. Another important observation was the accumulation of α-synuclein in the substantia nigra of rotenone treated rats, and cyclosporine A apparently did not have a major effect on the rotenone induced accumulation of α-synuclein in the substantia nigra (Fig. 2A and B–e). These results prompted us to explore the role of accumulated α-synuclein in rotenone mediated mPTP activation, mitochondrial functional impairment, and neuronal death in our models. For this purpose, we studied the effects of rotenone on mitochondrial functions and cell viability in SH-SY5Y cells with or without knocking down the protein expression of α-synuclein by specific siRNA. Our results clearly showed that knockdown of α-synuclein protein expression in SH-SY5Y cells with specific siRNA reduced the deleterious effects of rotenone on cell viability and mitochondrial functions (Fig. 3, Fig. 4). Taking the results from rotenone-based in vivo and in vitro PD models, we suggest that the accumulated α-synuclein presumably causes mitochondrial dysfunction through the activation of mPTP. From our group, such an interaction of α-synuclein with mPTP has been suggested in other in vitro models of neurodegeneration induced by lactacystin or ferric ammonium citrate [19,24]. However, we want to state explicitly that in all our earlier studies as well as the current study, we did not examine any actual molecular interactions between α-synuclein and mPTP subunits, and instead our mechanistic suggestion is inferential in nature based on the cyclosporine A inhibition of the process. Nevertheless, studies by other groups demonstrated direct interactions of α-synuclein with components of mPTP such as voltage-dependent anion channel (VDAC), adenine nucleotide translocase (ANT), and F-ATP synthase, producing varied effects on mPTP [[25], [26], [27]]. The activation of mPTP is known to cause a burst of ROS production, loss of mitochondrial membrane potential, and decreased ATP synthesis with eventual cell death by several regulated cell death pathways [13,28,29]. It may be pertinent here to explain why we have used undifferentiated instead of neuronally differentiated SH-SY5Y cells to establish the pivotal role of α-synuclein in rotenone cytotoxicity. The differentiated as well as the undifferentiated SH-SY5Y cells exhibit dopaminergic markers, and both types are extensively used in PD research, but it is still debated which of these two types is better suited for neurotoxicity studies [[30], [31], [32], [33]]. Technically, the undifferentiated SH-SY5Y cells in a proliferative state are easier to handle and manipulate in different experimental conditions, which prompted us to use undifferentiated cells. It will be interesting to point out that the protective effect of cyclosporine A against rotenone cytotoxicity in undifferentiated SH-SY5Y cells was largely validated in the PD rat model in our earlier study [12]. Likewise, as already mentioned, mitochondrial dysfunctions induced by rotenone in undifferentiated SH-SY5Y cells in the earlier study could also be reproduced in rotenone induced PD rats in the current study. Nevertheless, it may be stated that neuronally differentiated SH-SY5Y cells resemble the post-mitotic dopaminergic neurons of the substantia nigra more closely than undifferentiated SH-SY5Y cells; thus it would have been more appropriate to conduct α-synuclein knock down experiments with differentiated cells. The current study also highlights the potential neuroprotective function of cyclosporine A in PD, and this should be explored further in genetic models of PD. Cyclosporine A has shown its potential as a neuroprotective compound in traumatic brain injury or ischemic brain damage [34,35]. Given that cyclosporine A is a marketed immunosuppressive drug for several clinical conditions, its repurposing for neuroprotection in clinical PD may be relatively easy. Lastly, it may be mentioned that we have focused primarily on the mitochondrial aspect of rotenone toxicity and explained the protective action of cyclosporine A through interference with mitochondrial mechanisms in this study. However, we do not rule out that the immunosuppressive function of cyclosporine A has also contributed to its neuroprotective role in this PD model, especially because complex immunological mechanisms have been shown to be involved in PD pathogenesis [36]. CRediT authorship contribution statement Sukhpal Singh: Writing – original draft, Methodology, Investigation, Data curation, Conceptualization. Aritri Bir: Writing – review & editing, Writing – original draft, Methodology, Investigation, Data curation, Conceptualization. Rahul Thakur: Methodology, Investigation, Formal analysis. Aman Chauhan: Methodology, Investigation, Data curation. Arindam Ghosh: Methodology, Investigation, Formal analysis, Data curation. Amit Mittal: Writing – review & editing, Supervision, Methodology, Investigation, Formal analysis. Amit Kumar Nayak: Writing – review & editing, Formal analysis, Data curation. Sankha Shubhra Chakrabarti: Writing – review & editing, Writing – original draft, Formal analysis, Conceptualization. Sasanka Chakrabarti: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Ethics declaration This study was conducted in accordance with the following guidelines for animal welfare and/or reporting: COMPENDIUM OF CPCSEA (INDIA). This study was approved by the Animal Ethics Committee of the Maharishi Markandeshwar Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be University). (Approval No. MMIMSR/961 dated 29.07.2022) Funding The work was supported by a research grant to Sasanka Chakrabarti from Indian Council of Medical Research, New Delhi, India (Sanction No.5/4-5/191/Neuro/2019-NCD-I). Declaration of competing interest The authors declare no conflict of interest. Acknowledgements The authors wish to thank the authority of Maharishi Markandeshwar (Deemed to be University) and Adesh Medical College and Hospital for encouragement and administrative support. The authors acknowledge that the Graphical Abstract was drawn with the help of BioRender software. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.bbrep.2026.102783. Supplementary data The following are the Supplementary data to this article: Validation of knockdown of ά-synuclein protein expression by immunoblotting. The immunoblotting for α-synuclein was performed in Wild type, α-Syn KD and Scram cells. (a): Cells were incubated without or with rotenone and then subjected to immunoblotting for α- synuclein as described in the text; β-actin was used as the loading control. The ratio of band intensity of α-synuclein to the loading control is also shown as a number above the α-synuclein band for each lane. Knock down of α-synuclein protein expression is clearly observed in α-Syn KD cells. (b): Full-blot view of α-synuclein band with molecular weight markers. Validation of knockdown of ά-synuclein protein expression by immunoblotting. The immunoblotting for α-synuclein was performed in Wild type, α-Syn KD and Scram cells. (a): Cells were incubated without or with rotenone and then subjected to immunoblotting for α- synuclein as described in the text; β-actin was used as the loading control. The ratio of band intensity of α-synuclein to the loading control is also shown as a number above the α-synuclein band for each lane. Knock down of α-synuclein protein expression is clearly observed in α-Syn KD cells. (b): Full-blot view of α-synuclein band with molecular weight markers. Data availability Data will be made available on request. References Associated Data Data Availability Statement Data will be made available on request.